Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Xianchao Lin

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110518737. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 20

  1. Cancer antigen 125 levels change rule after laparoscopic biopsy and its prognostic value for patients with unresectable pancreatic ductal adenocarcinoma: a ret… Co-author DOI 10.1186/s12876-026-04688-7↗
  2. An exploratory study of serum creatine kinase as a prognostic marker for patients with resectable pancreatic cancer: looking into the relationship with body co… Co-author DOI 10.1186/s12937-025-01084-x↗
  3. Metabolic, transcriptomic, and proteomic adaptations in pancreatic ductal adenocarcinoma-patient derived xenograft models across serial passages. Co-author DOI 10.1186/s12967-025-06787-7↗
  4. Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor. First author DOI 10.1186/s12885-024-12193-x↗
  5. The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer. First author DOI 10.1186/s12885-023-11346-8↗
  6. A high serum creatine kinase (CK)-MB-to-total-CK ratio in patients with pancreatic cancer: a novel application of a traditional marker in predicting malignancy… First author DOI 10.1186/s12957-023-02903-3↗
  7. Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer. Co-author DOI 10.3389/fphar.2023.1193791↗
  8. Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer. Co-author DOI 10.3748/wjg.v28.i22.2468↗
  9. Laparoscopic biopsy and staging for locally advanced pancreatic cancer: experiences of 76 consecutive patients in a single institution. Co-author DOI 10.1007/s00423-021-02199-5↗
  10. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. Co-author DOI 10.1007/s00432-020-03463-9↗
  11. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer. Co-author DOI 10.1038/s41419-020-02787-1↗
  12. Photothermal augment stromal disrupting effects for enhanced Abraxane synergy chemotherapy in pancreatic cancer PDX mode. Co-author DOI 10.1039/d0bm00549e↗
  13. Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma Co-author DOI 10.1097/jp9.0000000000000055↗
  14. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Co-author DOI 10.1080/2162402x.2019.1581529↗
  15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0822-6↗
  16. WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC. Co-author DOI 10.1186/s13046-018-0848-6↗
  17. Non-invasively predicting differentiation of pancreatic cancer through comparative serum metabonomic profiling. Co-author DOI 10.1186/s12885-017-3703-9↗
  18. Identification and causes of metabonomic difference between orthotopic and subcutaneous xenograft of pancreatic cancer. Co-author DOI 10.18632/oncotarget.18057↗
  19. Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for … Co-author DOI 10.1039/c6mb00381h↗
  20. Metabonomic changes from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma in tissues from rats. Co-author DOI 10.1111/cas.12939↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heguang Huang · 18 shared papers, 2016–2025 · strength 2.52
  2. Fengchun Lu · 11 shared papers, 2018–2026 · strength 1.79
  3. Ronggui Lin · 7 shared papers, 2020–2026 · strength 1.35
  4. Yu Pan · 9 shared papers, 2018–2024 · strength 1.18
  5. Wen Shi · 7 shared papers, 2016–2025 · strength 0.91
  6. Congfei Wang · 4 shared papers, 2021–2026 · strength 0.89
  7. Cong Chen · 3 shared papers, 2023–2026 · strength 0.80
  8. Jianghua Feng · 6 shared papers, 2016–2025 · strength 0.74
  9. Tianhong Teng · 4 shared papers, 2020–2025 · strength 0.72
  10. Qinglin Fei · 5 shared papers, 2019–2021 · strength 0.53
  11. Xin Luo · 2 shared papers, 2023–2026 · strength 0.51
  12. Zelin Hou · 4 shared papers, 2019–2023 · strength 0.48
  13. Bohan Zhan · 4 shared papers, 2016–2024 · strength 0.44
  14. Yue Wu · 1 shared paper, 2026 · strength 0.32
  15. Minggui Pan · 3 shared papers, 2018–2019 · strength 0.27
  16. Pengfei Guo · 1 shared paper, 2025 · strength 0.23
  17. Maoen Pan · 2 shared papers, 2018–2020 · strength 0.20
  18. Jianfeng Gao · 1 shared paper, 2022 · strength 0.17
  19. Jiajing Lin · 1 shared paper, 2023 · strength 0.17
  20. Heguang Huang · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.